| Starling, Naureen |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
ZODIAC, NCT06250036: Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma |
|
|
| Not yet recruiting | 2 | 50 | NA | Single agent zimberelimab, Combination zimberelimab + domvanalimab | Royal Marsden NHS Foundation Trust, Gilead Sciences | Metastatic Esophageal Cancer, Metastatic Gastric Cancer | 09/26 | 09/31 | | |
AZUR-4, NCT06567782: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer |
|
|
| Not yet recruiting | 2 | 120 | Europe | Dostarlimab, GSK4057190A, TSR-042, CAPEOX | GlaxoSmithKline | Neoplasms, Colon | 09/28 | 09/28 | | |
| Recruiting | 2 | 500 | Europe | FOLFOX-A, Gemcitabe and Abraxane, G-CSF | Judith Dixon-Hughes, NHS Greater Glasgow and Clyde, University of Glasgow | Neoplasms Pancreatic | 12/25 | 01/26 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
PREVAILctDNA, NCT04566614: Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies |
|
|
| Recruiting | N/A | 294 | Europe | ctDNA blood sampling | Royal Marsden NHS Foundation Trust | Neoplasm, Colorectal, Neoplasm of Lung, Neoplasm, Bladder, Neoplasms Pancreatic, Biliary Tract Neoplasms, Gastro Intestinal Stromal Tumour | 07/23 | 12/25 | | |
NCT04161417: Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer |
|
|
| Recruiting | N/A | 2500 | Europe | Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling | Judith Dixon-Hughes, Cancer Research UK, NHS Greater Glasgow and Clyde | Neoplasms Pancreatic | 12/25 | 12/25 | | |
| Moorcraft, Sing Yu |
SALUTE, NCT06142071: Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting |
|
|
| Active, not recruiting | N/A | 50 | Europe | Telephone questionnaire | Swansea Bay University Health Board, Swansea University | Cancer | 09/24 | 09/24 | | |
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer |
|
|
| Recruiting | N/A | 1000 | Europe | | Royal Marsden NHS Foundation Trust | Colorectal Cancer | 07/29 | 07/31 | | |
| Woodburne, Annie |
| No trials found |
